Form 4 for PYXS Pyxis Oncology, Inc.
Accepted 2023-03-28 00:00:00 ET · period of report 2023-03-24 · accession 0001209191-23-021415 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-28 | 2023-03-24 | PYXS | Sullivan Lara | Pres, CEO, Dir | A - Grant | $0.00 | +703.4K | 2.16M | +48% | $0 |
| DM | 2023-03-28 | 2023-03-24 | PYXS | Sullivan Lara | Pres, CEO, Dir | D - Sale to Iss | — | -1.05M | 0 | -100% | — |
| DM | 2023-03-28 | 2023-03-24 | PYXS | Sullivan Lara | Pres, CEO, Dir | A - Grant | — | +1.05M | 61.8K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-24 | A | A | 703,379 | $0.00 | 2,155,699 | D | — | — | (F1) Represents restricted stock units that vest 25% on March 24, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. |
| 2 | Derivative | Stock Option (Right to buy) | 2023-03-24 | D | D | 990,461 | — | 0 | D | $5.34 · — to 2031-03-30 | 990,461 Common Stock | (F2) In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. (F3) These stock options vest in 48 substantially-equal monthly installments beginning January 2, 2020, subject to the reporting person's continued employment through the applicable vesting date. |
| 3 | Derivative | Stock Option (Right to buy) | 2023-03-24 | D | D | 61,825 | — | 0 | D | $8.71 · — to 2031-09-14 | 61,825 Common Stock | (F2) In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. (F4) These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. |
| 4 | Derivative | Stock Option (Right to buy) | 2023-03-24 | A | A | 990,461 | — | 990,461 | D | $2.21 · — to 2031-03-30 | 990,461 Common Stock | (F2) In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. (F3) These stock options vest in 48 substantially-equal monthly installments beginning January 2, 2020, subject to the reporting person's continued employment through the applicable vesting date. |
| 5 | Derivative | Stock Option (Right to buy) | 2023-03-24 | A | A | 61,825 | — | 61,825 | D | $2.21 · — to 2031-09-14 | 61,825 Common Stock | (F2) In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. (F4) These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. |